Gao 2010.

Methods	Randomized controlled trial.
Participants	249 people undergoing primary isolated CABG, with or without cardiopulmonary bypass who received ≥ 1 SVG.
Interventions	Aspirin 100 mg plus clopidogrel 75 mg (n = 124; mean age (± SD) 57.9 ± 8.25 years, female sex 17.7%) for 3 months. Aspirin 100 mg (n = 125; mean age (± SD) 59.8 ± 7.92 years, female sex 16.2%) for 3 months.
Outcomes	Primary: MSCT angiography. Secondary: MACEs, defined as: cardiogenic death; MI (hospital visit for MI reported by participant or hospital admission for MI reported by cardiologist); and need for revascularization (repeat operation or angioplasty reported by participant or cardiologist) through 3 months after CABG.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients with successful CABG surgery were randomly assigned to 2 groups."
Allocation concealment (selection bias)	Unclear risk	"Patients with successful CABG surgery were randomly assigned to 2 groups."
Blinding (performance bias and detection bias) All outcomes	High risk	"The current trials were carried out in a single center without placebo control ... In addition to the MSCTA [multislice computed tomography angiography] observers, the investigator and patients were not blinded to the randomized allocation."
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Two‐hundred forty‐nine cardiac surgery candidates were randomized to group A [aspirin alone] (n=125) or group AC [aspirin plus clopidogrel] (n=124). Of the 249 participants, 1 (0.4%) (from group A) died at 6 weeks after CABG surgery. Of the remaining 248 patients, 239 (96.4%) completed a 3‐month follow‐up, and 224 (90.3%) underwent MSCTA. Deaths, numbers and reasons for loss to follow‐up, and numbers contributing to analyses are shown in Figure 1."
Selective reporting (reporting bias)	Unclear risk	Mostly reported as per protocol, but major bleeding not reported.
Other bias	Low risk	"This study was supported by the Key Project in the National Science & Technology Pillar Program during the 11th 5‐Year Plan Period (2006BAI01A09)."